A comparative study of sorafenib and metronomic chemotherapy for Barcelona Clinic Liver Cancer-stage C hepatocellular carcinoma with poor liver function
Open Access
- 25 June 2017
- journal article
- research article
- Published by The Korean Association for the Study of the Liver in Clinical and Molecular Hepatology
- Vol. 23 (2), 128-137
- https://doi.org/10.3350/cmh.2016.0071
Abstract
Background/Aims: Metronomic chemotherapy (MET) is frequently administered in comparatively low doses as a continuous chemotherapeutic agent. The aim of this study was to evaluate the feasibility and overall survival (OS) of MET compared to sorafenib for advanced hepatocellular carcinoma (HCC) patients with portal vein tumor thrombosis (PVTT). Methods: A total of 54 patients with advanced HCC and PVTT who had undergone MET were analyzed between 2005 and 2013. A total of 53 patients who had undergone sorafenib therapy were analyzed as the control group. The primary endpoint of this study was OS. Results: The median number of MET cycles was two (1-15). The OS values for the MET group and sorafenib group were 158 days (132-184) and 117 days (92-142), respectively (P=0.029). The Cox proportional-hazard model showed that a higher risk of death was correlated with higher serum alpha fetoprotein level (>= 400 mg/dL, hazard ratio [HR]=1.680, P=0.014) and Child-Pugh class B (HR=1.856, P=0.008). Conclusions: MET was associated with more favorable outcomes in terms of overall survival than was sorafenib in patients with advanced HCC with PVTT, especially in patients with poor liver function. Therefore, MET can be considered as a treatment option in patients with advanced HCC with PVTT and poor liver function.Keywords
This publication has 26 references indexed in Scilit:
- Clinical outcomes of patients with advanced hepatocellular carcinoma treated with sorafenib: a retrospective study of routine clinical practice in multi-institutionsBMC Cancer, 2015
- Safety and efficacy of sorafenib in patients with Child-Pugh B advanced hepatocellular carcinomaMolecular and Clinical Oncology, 2015
- Global cancer statistics, 2012CA: A Cancer Journal for Clinicians, 2015
- New perspectives on the management of hepatocellular carcinoma with portal vein thrombosisClinical and Molecular Hepatology, 2015
- Sorafenib for hepatocellular carcinoma according to Child-Pugh class of liver functionCancer Chemotherapy and Pharmacology, 2011
- Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trialThe Lancet Oncology, 2008
- Sorafenib in Advanced Hepatocellular CarcinomaThe New England Journal of Medicine, 2008
- Hepatocellular carcinomaThe Lancet, 2003
- Less is more, regularly: metronomic dosing of cytotoxic drugs can target tumor angiogenesis in miceJCI Insight, 2000
- Prognosis of Hepatocellular Carcinoma: The BCLC Staging ClassificationSeminars in Liver Disease, 1999